PHVS · Company research
Pharvaris N.V. Ordinary Shares (PHVS): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
17records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Pharvaris N.V. (PHVS) stock price, news, quote and history - Yahoo Finance Singapore | Pharvaris N.V. (PHVS) stock price, news, quote and history Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 10, 2026 | neutral | 0 | 0.6 |
| Pharvaris N.V. (PHVS) Stock Price, News, Quote & History - Yahoo! Finance Canada | Pharvaris N.V. (PHVS) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 9, 2026 | neutral | 0 | 0.6 |
| Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet | Pharvaris announced that Phase 3 RAPIDe-3 trial results for deucrictibant IR, an oral bradykinin B2 receptor antagonist for on-demand treatment of hereditary angioedema (HAE) attacks, were published in The Lancet. The drug achieved symptom relief in 1.28 hours and complete resolution in 11.95 hours, met its primary endpoint and all 11 secondary endpoints, and showed a well-tolerated safety profile. An NDA with the FDA (PDUFA target date April 23, 2027) and MAA with the EMA are currently under regulatory review. | View source ↗ | GlobeNewswire Inc. | Oct 8, 2026 | bullish | 1 | 1 |
| Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet | Pharvaris announced that Phase 3 RAPIDe-3 trial results for deucrictibant IR, an oral bradykinin B2 receptor antagonist for on-demand treatment of hereditary angioedema (HAE) attacks, were published in The Lancet. The drug achieved symptom relief in 1.28 hours and complete resolution in 11.95 hours, met its primary endpoint and all 11 secondary endpoints, and showed a well-tolerated safety profile. An NDA with the FDA (PDUFA target date April 23, 2027) and MAA with the EMA are currently under regulatory review. | View source ↗ | GlobeNewswire Inc. | Oct 8, 2026 | bullish | 1 | 1 |
| Pharvaris N.V. (PHVS) stock price, news, quote and history - Yahoo Finance Australia | Pharvaris N.V. (PHVS) stock price, news, quote and history Yahoo Finance Australia | View source ↗ | Yahoo Finance Australia | Oct 6, 2026 | neutral | 0 | 0.6 |
| Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy | Pharvaris-funded analysis of real-world HAE management reveals significant gaps between guideline-recommended care and clinical practice. Study of 225 physicians and 279 patients identified key barriers to treatment adherence, including treatment burden, route of administration, and patient perception of attack severity. Findings highlight unmet needs and suggest oral daily treatment is preferred over injectable options, supporting Pharvaris' development of oral bradykinin B2 receptor antagonists. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bullish | 1 | 1 |
| Many people with an inherited swelling disorder don't treat every attack - Stock Titan | Many people with an inherited swelling disorder don't treat every attack Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Planned $7M Pharvaris (NASDAQ: PHVS) stock sale disclosed for founder shares - Stock Titan | Planned $7M Pharvaris (NASDAQ: PHVS) stock sale disclosed for founder shares Stock Titan | View source ↗ | Stock Titan | Sep 22, 2026 | neutral | 0 | 0.6 |
| After $7M stock sale, Pharvaris (NASDAQ: PHVS) director plans more - Stock Titan | After $7M stock sale, Pharvaris (NASDAQ: PHVS) director plans more Stock Titan | View source ↗ | Stock Titan | Sep 22, 2026 | neutral | 0 | 0.6 |
| Pharvaris (NASDAQ: PHVS) officer plans Rule 144 sale of 6,000 shares - Stock Titan | Pharvaris (NASDAQ: PHVS) officer plans Rule 144 sale of 6,000 shares Stock Titan | View source ↗ | Stock Titan | Sep 21, 2026 | neutral | 0 | 0.6 |
| PHVS Stock Rises 10% in a Month: What Is Driving the Rally? - Yahoo Finance | PHVS Stock Rises 10% in a Month: What Is Driving the Rally? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 15, 2026 | neutral | 0 | 0.6 |
| $PHVS stock is up 14% today. Here's what we see in our data. - Quiver Quantitative | $PHVS stock is up 14% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 8, 2026 | neutral | 0 | 0.6 |
| Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment (NASDAQ:PHVS) - Seeking Alpha | Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment (NASDAQ:PHVS) Seeking Alpha | View source ↗ | Seeking Alpha | Aug 4, 2026 | neutral | 0 | 0.6 |
| Pharvaris (PHVS) Stock May Be Pricey After A 103% Five Year Run - Yahoo Finance | Pharvaris (PHVS) Stock May Be Pricey After A 103% Five Year Run Yahoo Finance | View source ↗ | Yahoo Finance | Aug 3, 2026 | neutral | 0 | 0.6 |
| Why This Biotech, Up 12% Since Its Breakout, Yo-Yoed On A Key FDA Development - Investor's Business Daily | Why This Biotech, Up 12% Since Its Breakout, Yo-Yoed On A Key FDA Development Investor's Business Daily | View source ↗ | Investor's Business Daily | Jul 6, 2026 | neutral | 0 | 0.6 |
| Pharvaris wins FDA review for oral HAE attack treatment - Stock Titan | Pharvaris wins FDA review for oral HAE attack treatment Stock Titan | View source ↗ | Stock Titan | Jul 6, 2026 | neutral | 0 | 0.6 |
| PHVS Stock Price and Chart — NASDAQ:PHVS - TradingView | PHVS Stock Price and Chart — NASDAQ:PHVS TradingView | View source ↗ | TradingView | Feb 24, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.